Dimitri Laurent

Dimitri Laurent

Auto-generated profile, based on publicly available information

Dimitri Laurent

University of Florida

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
WDWilliam S Dodd
William S Dodd
DLDimitri Laurent
Dimitri Laurent
ADAaron S. Dumont
Aaron S. Dumont
DHDavid Hasan
David Hasan
PJPascal Jabbour
Pascal Jabbour
NCNohra Chalouhi
Nohra Chalouhi
Delayed cerebral ischemia is a major predictor of poor outcomes in patients who suffer subarachnoid hemorrhage. Treatment options are limited and often ineffective despite many years of investigation and clinical trials. Modern advances in basic science have produced a much more complex, multifactorial framework in which delayed cerebral ischemia is better understood and novel treatments can be developed. Leveraging this knowledge to improve outcomes, however, depends on a holistic understanding of the disease process. We conducted a review of the literature to analyze the current state of investigation into delayed cerebral ischemia with emphasis on the major themes that have emerged over the past decades. Specifically, we discuss microcirculatory dysfunction, glymphatic impairment, inflammation, and neuroelectric disruption as pathological factors in addition to the canonical focus on cerebral vasospasm. This review intends to give clinicians and researchers a summary of the foundations of delayed cerebral ischemia pathophysiology while also underscoring the interactions and interdependencies between pathological factors. Through this overview, we also highlight the advances in translational studies and potential future therapeutic opportunities.

24 March 2023 in Science
Verified
Journal Article
Closed access
SDSenthilkumar Duraivel
Senthilkumar Duraivel
DLDimitri Laurent
Dimitri Laurent
DRDidier A. Rajon
Didier A. Rajon
GSGeorg M. Scheutz
Georg M. Scheutz
ASAbhishek M. Shetty
Abhishek M. Shetty
TAThomas E. Angelini
Thomas E. Angelini
Among the diverse areas of 3D printing, high-quality silicone printing is one of the least available and most restrictive. However, silicone-based components are integral to numerous advanced technologies and everyday consumer products. We developed a silicone 3D printing technique that produces precise, accurate, strong, and functional structures made from several commercially available silicone formulations. To achieve this level of performance, we developed a support material made from a silicone oil emulsion. This material exhibits negligible interfacial tension against silicone-based inks, eliminating the disruptive forces that often drive printed silicone features to deform and break apart. The versatility of this approach enables the use of established silicone formulations in fabricating complex structures and features as small as 8 micrometers in diameter.

1 January 2022 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
DLDimitri Laurent
Dimitri Laurent
CSCoulter Small
Coulter Small
BLBrandon Lucke-Wold
Brandon Lucke-Wold
WDWilliam S. Dodd
William S. Dodd
NCNohra Chalouhi
Nohra Chalouhi
BHBrian L. Hoh
Brian L. Hoh

25 July 2019 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
DLDimitri Laurent
Dimitri Laurent
RFRachel Freedman
Rachel Freedman
LCLogan Cope
Logan Cope
PSPatricia Sacks
Patricia Sacks
JAJoe Abbatematteo
Joe Abbatematteo
MRMaryam Rahman
Maryam Rahman
BACKGROUND: Extent of resection (EOR) is well established as correlating with overall survival in patients with glioblastoma (GBM). The impact of EOR on reported quality metrics such as patient safety indicators (PSIs) and hospital-acquired conditions (HACs) is unknown. OBJECTIVE: To perform a retrospective study to evaluate possible associations between EOR and the incidence of PSIs and HACs. METHODS: We queried all patients diagnosed with GBM who underwent surgical resection at our institution between January 2011 and May 2017. Pre- and postoperative magnetic resonance images were analyzed for EOR. Each chart was reviewed to determine the incidence of PSIs and HACs. RESULTS: A total of 284 patients met the inclusion criteria. EOR ranged from 39.00 to 100%, with a median of 99.84% and a mean of 95.7%. There were 16 PSI, and 13 HAC, events. There were no significant differences in the rates of PSIs or HACs when compared between patients stratified by gross total resection (EOR ≥ 95%) and subtotal resection (EOR < 95%). The odds of encountering a PSI or HAC were 2.5 times more likely in the subtotal resection group compared to the gross total resection group (P = .58). After adjusting for confounders, the odds of encountering a PSI or HAC in the subtotal resection group were 3.9 times greater than for the gross total resection group (P < .05). CONCLUSION: Gross total resection of GBM is associated with a decreased incidence of PSIs and HACs, as compared to subtotal resection.

2 July 2021 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
DLDimitri Laurent
Dimitri Laurent
WDWilliam S Dodd
William S Dodd
CSCoulter Small
Coulter Small
MGM Reid Gooch
M Reid Gooch
RGRitam Ghosh
Ritam Ghosh
NCNohra Chalouhi
Nohra Chalouhi
The placement of cervical and intracranial stents requires the administration of antiplatelet drugs to prevent thromboembolic complications. Ticagrelor has emerged as the most widely used alternative in clopidogrel non-responders owing to its potent antiplatelet effects. Because ticagrelor does not require hepatic activation, many neurointerventionalists choose to forgo laboratory testing of platelet inhibition. In rare instances, patients may not achieve adequate platelet inhibition following ticagrelor administration. In this paper we review the mechanism of action of ticagrelor and its use in cerebrovascular procedures. We present two cases of ticagrelor non-responsiveness from two high-volume cerebrovascular centers, discuss their management, and propose an algorithm for managing ticagrelor non-responsiveness.

1 April 2013 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
PDF file
SHSteven D. Hicks
Steven D. Hicks
NLN. Labinskyy
N. Labinskyy
BPB. Piteo
B. Piteo
DLD. Laurent
D. Laurent
JMJ. E. Mathew
J. E. Mathew
JEJohn Edwards
John Edwards
Mitochondrial dysfunction has a significant role in the development of diabetic cardiomyopathy. Mitochondrial oxidant stress has been accepted as the singular cause of mitochondrial DNA (mtDNA) damage as an underlying cause of mitochondrial dysfunction. However, separate from a direct effect on mtDNA integrity, diabetic-induced increases in oxidant stress alter mitochondrial topoisomerase function to propagate mtDNA mutations as a contributor to mitochondrial dysfunction. Both glucose-challenged neonatal cardiomyocytes and the diabetic Goto-Kakizaki (GK) rat were studied. In both the GK left ventricle (LV) and in cardiomyocytes, chronically elevated glucose presentation induced a significant increase in mtDNA damage that was accompanied by decreased mitochondrial function. TTGE analysis revealed a number of base pair substitutions in the 3' end of COX3 from GK LV mtDNA that significantly altered the protein sequence. Mitochondrial topoisomerase DNA cleavage activity in isolated mitochondria was significantly increased in the GK LV compared with Wistar controls. Both hydroxycamptothecin, a topoisomerase type 1 inhibitor, and doxorubicin, a topoisomerase type 2 inhibitor, significantly exacerbated the DNA cleavage activity of isolated mitochondrial extracts indicating the presence of multiple functional topoisomerases in the mitochondria. Mitochondrial topoisomerase function was significantly altered in the presence of H2O2suggesting that separate from a direct effect on mtDNA, oxidant stress mediated type II diabetes-induced alterations of mitochondrial topoisomerase function. These findings are significant in that the activation/inhibition state of the mitochondrial topoisomerases will have important consequences for mtDNA integrity and the well being of the diabetic myocardium.